Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron (RVT-901)

Our lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. We have initiated an international Phase 3 registration program for vibegron.

LEARN MORE

women-sleeping

Overactive Bladder (OAB)

Overactive bladder (OAB) is a condition that affects potentially 46 million American adults. The most common symptoms of OAB include the experience of sudden urges to urinate that cannot be controlled, frequent urination, and urinary incontinence due to involuntary contractions of the detrusor muscle. While several conditions may contribute to signs and symptoms of overactive bladder, the underlying cause of OAB remains unclear.

LEARN MORE

woman-drinking-on-hike

Latest News

The latest posts and articles

Urovant Sciences Strengthens Executive Management…

Cornelia Haag-Molkenteller, former VP and Therapeutic Area Head, Clinical Development, for Urology, Women’s Health, and…

Urovant Sciences Initiates Phase 3…

Pivotal trial will enroll approximately 1,400 patients for 12-week treatment period Program supported by prior…

Urovant Sciences Announces Upcoming Presentations…

Urovant Sciences, today announced that clinical data from a Phase 2b study of vibegron will…

Copyright 2018 © All Rights Reserved